McVary K T, Polepalle S, Riggi S, Pelham R W
Department of Urology, Northwestern University Medical School, Chicago, Illinois, USA.
J Urol. 1999 Sep;162(3 Pt 1):726-30; discussion 730-1. doi: 10.1097/00005392-199909010-00025.
We compare the systemic effects, local tolerance and effectiveness of topical gel formulations on the penis containing alprostadil (prostaglandin E1) plus 5% SEPA versus SEPA alone (placebo) in men with erectile dysfunction.
Erectile response, skin discomfort and erythema were measured in 48 men with erectile dysfunction secondary to vascular, neurogenic, psychogenic or mixed etiologies in this single-blind, placebo controlled trial.
Application of prostaglandin E1 gel correlated positively with erectile response as 67 to 75% of patients had an erection compared to 17% of controls (p<0.001). Blood pressure and heart rate varied minimally. No serious adverse effects were observed in the 48 patients, although the majority had skin discomfort.
Topical prostaglandin E1 gel applied to the penis appears to be safe, and facilitates audiovisual and tactile stimulation resulting in an erection when given in a clinic setting. Consequences to the female partner remain unknown.
我们比较了含前列地尔（前列腺素E1）加5% SEPA的阴茎局部凝胶制剂与单独使用SEPA（安慰剂）对勃起功能障碍男性的全身影响、局部耐受性和有效性。
在这项单盲、安慰剂对照试验中，对48例继发于血管性、神经性、心理性或混合性病因的勃起功能障碍男性测量勃起反应、皮肤不适和红斑。
前列腺素E1凝胶的应用与勃起反应呈正相关，67%至75%的患者出现勃起，而对照组为17%（p<0.001）。血压和心率变化极小。48例患者中未观察到严重不良反应，尽管大多数患者有皮肤不适。
阴茎局部应用前列腺素E1凝胶似乎是安全的，并且在临床环境中给予时有助于视听和触觉刺激从而导致勃起。对女性伴侣的影响尚不清楚。
